Tyche Wealth Partners LLC Has $603,000 Stock Holdings in Pfizer Inc. $PFE

Tyche Wealth Partners LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.7% in the second quarter, HoldingsChannel.com reports. The fund owned 24,877 shares of the biopharmaceutical company’s stock after selling 954 shares during the quarter. Tyche Wealth Partners LLC’s holdings in Pfizer were worth $603,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. KLP Kapitalforvaltning AS raised its stake in Pfizer by 10.7% in the second quarter. KLP Kapitalforvaltning AS now owns 3,007,432 shares of the biopharmaceutical company’s stock valued at $72,900,000 after purchasing an additional 289,900 shares in the last quarter. RMG Wealth Management LLC bought a new position in Pfizer in the 2nd quarter valued at about $80,000. Hardy Reed LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $223,000. Seamount Financial Group Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $226,000. Finally, SteelPeak Wealth LLC lifted its holdings in shares of Pfizer by 16.4% during the 2nd quarter. SteelPeak Wealth LLC now owns 257,256 shares of the biopharmaceutical company’s stock worth $6,236,000 after acquiring an additional 36,195 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 3.4%

NYSE PFE opened at $26.45 on Tuesday. The company has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business’s fifty day moving average is $24.72 and its 200 day moving average is $24.12.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.